Celldex Therapeutics, Inc.
CLDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $7 | $7 | $2 | $5 |
| % Growth | 2% | 192% | -49.3% | – |
| Cost of Goods Sold | $164 | $118 | $82 | $53 |
| Gross Profit | -$157 | -$111 | -$80 | -$49 |
| % Margin | -2,229.8% | -1,614.5% | -3,389.9% | -1,046.2% |
| R&D Expenses | $164 | $118 | $82 | $57 |
| G&A Expenses | $39 | $31 | $27 | $20 |
| SG&A Expenses | $39 | $31 | $27 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$164 | -$106 | -$74 | -$55 |
| Operating Expenses | $39 | $43 | $35 | $23 |
| Operating Income | -$195 | -$155 | -$115 | -$71 |
| % Margin | -2,778.9% | -2,245.3% | -4,889% | -1,531.8% |
| Other Income/Exp. Net | $37 | $13 | $3 | $1 |
| Pre-Tax Income | -$158 | -$141 | -$112 | -$70 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$158 | -$141 | -$112 | -$71 |
| % Margin | -2,248.8% | -2,054.8% | -4,765.6% | -1,516% |
| EPS | -2.45 | -2.92 | -2.4 | -1.64 |
| % Growth | 16.1% | -21.7% | -46.3% | – |
| EPS Diluted | -2.45 | -2.92 | -2.4 | -1.64 |
| Weighted Avg Shares Out | 64 | 48 | 47 | 43 |
| Weighted Avg Shares Out Dil | 64 | 48 | 47 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $37 | $13 | $3 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $3 | $3 | $3 |
| EBITDA | -$192 | -$139 | -$104 | -$66 |
| % Margin | -2,733.6% | -2,020% | -4,420.9% | -1,420.8% |